Abstract
Enhanced brain delivery of zidovudine (AZT) has been demonstrated using a redox-based chemical delivery system (CDS). Optimization of the prototype AZT-CDS (5′-[(1-methyl-1,4-dihydropyridin-3-yl)carbonyl]-3′-azido-3′-deoxythymidine) was investigated by manipulation of the N-methyl group present on the dihydronicotinate portion of the molecule and examining the release of AZT in vivo in a rat model. Of the five compounds examined, all produced higher brain levels and lower blood levels of AZT than did AZT itself. In comparing the novel AZT-CDS analogues to the N-methyl benchmark, the N-propyl system proved to be the most efficient of the compounds tested.
Similar content being viewed by others
REFERENCES
A. Pajeau and G. Roman. HIV encephalopathy and dementia. Psychiat. Clin. No. Am. 15:455–466 (1992).
I. Reinvang, S. Froland, and V. Skripeland. Prevalence of neuropsychological deficit in HIV. Acta Neurol. Scand. 83:289–293 (1991).
J. Brew, M. Rosenblum, and R. Price. AIDS dementia complex and primary brain infection. J. Neuroimmunol. 20:133–140 (1988).
S. Rapoport. The Blood-Brain Barrier in Physiology and Medicine, Raven Press, New York, 1976.
E. Neuwelt. Implications of the Blood-Brain Barrier in Physiology and Medicine, Plenum Press, New York, 1989.
S. Wong, Y. Wong, and R. Sawchuk. Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis. Pharm. Res. 9:332–338 (1992).
T. Kawaguchi, K. Ishikawa, T. Seki, and K. Juni. Ester prodrugs of zidovudine. J. Pharm. Sci. 79:531–533 (1990).
A. Namane, C. Gouyette, M. Fillion, G. Fillion, and T. Huynh-Dinh. Improved brain delivery using a glycosyl phosphotriester prodrug. J. Med. Chem. 35:3039–3044 (1992).
V. Stella and K. Himmelstein. Prodrugs and site-specific drug delivery. J. Med. Chem. 23:1275–1282 (1980).
J. Gorrod. Potential hazards of the prodrug approach. Chem. Indust. 11:458–462 (1980).
N. Bodor, H. Farag, and M. Brewster. Site-specific, sustained release of drugs to the brain. Science 214:1370–1372 (1981).
N. Bodor and M. Brewster. Chemical delivery systems. In R. Juliano (ed.), Handbook of Experimental Pharmacology, Vol. 100. Targeted Drug Delivery, Springer-Verlag, Berlin, 1991, pp. 231–284.
R. Little, D. Bailey, M. Brewster, K. Estes, R. Clemmons, A. Saab, and N. Bodor. Improved delivery through biological membranes. XXXIII. Brain-enhanced delivery of azidothymidine (AZT). J. Biopharm. Sci. 1:1–18 (1990).
P. Torrence, J. Kinjo, K. Lesiak, J. Balzarini, and E. De Clercq. AIDS dementia: Synthesis and properties of a derivative of 3′-azido-3′-deoxythymidine (AZT) that may become “locked” in the central nervous system. FEBS Lett. 234:135–140 (1988).
M. Brewster, W. Anderson, and N. Bodor. Brain, blood and cerebrospinal fluid distribution of a zidovudine chemical delivery system in rabbits. J. Pharm. Sci. 80:843–846 (1991).
C. Chu, V. Bhadti, K. Doshi, J. Etse, J. Gallo, F. Boudinot, and R. Schinazi. Brain targeting of anti-HIV nucleosides: Synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine. J. Med. Chem. 33:2188–2192 (1990).
J. Gallo, J. Etse, K. Doshi, F. Boudinot, and C. Chu. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm. Res. 8:247–253 (1991).
S. Gogu, S. Aggarwal, S. Rangan, and K. Agrawal. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem. Biophys. Res. Commun. 160:656–661 (1989).
S. Aggarwal, S. Gogu, S. Rangan, and K. Agrawal. Synthesis and biological evaluation of prodrugs of zidovudine. J. Med. Chem. 33:1505–1510 (1990).
T. Yamana, A. Tsuji, E. Miyamoto, and O. Kubo. Novel method for the determination of partition coefficients of penicillins and cephalosporins by high-pressure liquid chromatography. J. Pharm. Sci. 66:747–749 (1977).
M. Brewster, A. Simay, K. Czako, D. Winwood, H. Farag, and N. Bodor. Reactivity of biologically important reduced pyridines. 4. Effect of substitution on ferricyanide-mediated oxidation rates of various 1,4-dihydropyridines. J. Org. Chem. 45:3721–3726 (1989).
E. Pop, M. Brewster, W. Anderson, and N. Bodor. Biodistribution of azidothmidine mediated by a highly lipophilic chemical delivery system. Med. Chem. Res. 2:457–466 (1992).
M. Blum, S. Liao, S. Good, and P. de Miranda. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85(Suppl. 2A):189–194 (1988).
P. Cload. A review of the pharmacokinetics of zidovudine in man. J. Infect. 18(Suppl. 1):15–21 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brewster, M.E., Pop, E., Braunstein, A.J. et al. The Effect of Dihydronicotinate N-Substitution on the Brain-Targeting Efficacy of a Zidovudine Chemical Delivery System. Pharm Res 10, 1356–1362 (1993). https://doi.org/10.1023/A:1018986217181
Issue Date:
DOI: https://doi.org/10.1023/A:1018986217181